Stereotactic Body Radiotherapy – Current Indications
Authors:
P. Burkoň 1,2; M. Slavik 1,2; T. Kazda 1,2,3; P. Pospíšil 1,2; T. Prochazka 1,2; M. Vrzal 1; P. Šlampa 1,2
Authors‘ workplace:
Klinika radiační onkologie, Masarykův onkologický ústav, Brno
1; Klinika radiační onkologie, LF MU, Brno
2; CEITEC – Středoevropský technologický institut, Masarykova univerzita, Brno
3
Published in:
Klin Onkol 2019; 32(1): 10-24
Category:
Review
doi:
https://doi.org/10.14735/amko201910
Overview
Background:
Stereotactic body radiotherapy (SBRT) is used to treat localized tumor lesions and consists of applying high doses of radiation to a small number of fractions using specially equipped linear accelerators, modern immobilization devices, and imaging methods, which are considered special, advanced techniques in modern day radiotherapy. SBRT is a very well tolerated, non-invasive, short-term treatment that does not require hospitalization or any complicated preparation. Compared to standard radiotherapy techniques, SBRT allows, due to its precision, significantly higher doses to be applied to the target with less damage to surrounding healthy tissues. If dose constraints are not exceeded, the risk of damage to tissues and organs around the irradiated volume is reduced to minimum. The principle of SBRT is the application of ablative doses of radiation that cause necrosis of the irradiated tissue.
Purpose:
The aim of this review is to provide a basic overview of SBRT indications, radiation doses used, and potential side effects. It is not intended to be a detailed description of treatment itself (such as discussion of patient fixation systems, management of respiratory movements, or image guided strategies of treatment). This review also discusses rarer indications for SBRT, such as pancreatic carcinoma or hepatocellular carcinoma.
Conclusion:
Advances in image navigation, radiation planning, and dose application have enabled successful introduction of SBRT as a treatment regimen for many primary tumors and oligometastatic disease. If surgery is not possible or the patient refuses surgery, it is always reasonable to consider SBRT. SBRT has curative potential for the treatment of primary lung or prostate tumors. High-dose irradiation of oligometastases of various primary tumors can lead to long-term survival without disease symptoms, delay administration of toxic systemic therapies, and improve the quality of life of oncological patients.
Key words
radiotherapy – stereotactic body radiotherapy – review – ablative radiotherapy – lung cancer – prostate cancer – oligometastatic disease
This work was supported in part by the Ministry of Health, Czech Republic – Conceptual Development of Research Organization (MMCI 00209805). The results of this research have been acquired within CEITEC 2020 (LQ1601) project with the financial contribution made by the Ministry of Education, Youths and Sports of the Czech Republic within special support paid from the National Programme for Sustainability II funds.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted: 30. 10. 2018
Accepted: 4. 11. 2018
Sources
1. Lo SS, Teh BS, Lu JJ et al (eds). Stereotactic body radiation therapy, medical radiology. Heidelberg: Springer-Verlag Berlin 2012.
2. Burkoň P. Extrakraniální stereotaktická radioterapie. In: Šlampa P et al. Radiační onkologie v praxi. 4. vyd. Brno: MOÚ 2016.
3. Čoupek P, Burkoň P, Dymáčková R et al. Postavení radioterapie v léčbě bronchogenního karcinomu. Klin Onkol 2016; 29 (Suppl 2): S297–S298.
4. Burkoň P, Kazda T, Slávik M. Efekt akcelerované radioterapie u plicního adenokarcinomu. Klin Onkol 2015; 28 (1): 64–65.
5. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1–19. doi: 10.1007/978-3-319-24223-1_1.
6. Howington JA, Blum MG, Chang AC et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (Suppl 5): e278S–313S. doi: 10.1378/chest.12-2359.
7. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11): 1070–1076. doi: 10.1001/jama.2010.261.
8. Baumann P, Nyman J, Hoyer M et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27 (20): 3290–3296. doi: 10.1200/JCO.2008.21.5681.
9. Onishi H, Shirato H, Nagata Y et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011; 81 (5): 1352–1358. doi: 10.1016/j.ijrobp.2009.07.1751.
10. Grutters JP, Kessels AG, Pijls-Johannesma M et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010; 95 (1): 32–40. doi: 10.1016/j.radonc.2009.08.003.
11. Palma D, Visser O, Lagerwaard FJ et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28 (35): 5153–5159. doi: 10.1200/JCO.2010.30.0731.
12. Shirvani SM, Jiang J, Chang JY et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84 (5): 1060–1070. doi: 10.1016/j.ijrobp.2012.07.2354.
13. Ettinger DS, Wood DE, Aisner DL et al. NCCN Guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16 (7): 807–821. doi: 10.6004/jnccn.2018.0062.
14. Postmus PE, Kerr KM, Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl 4): 1–21. doi: 10.1093/annonc/mdx222.
15. Videtic GM, Donington J, Giuliani M et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7 (5): 295–301. doi: 10.1016/j.prro.2017.04.014.
16. Chang JY, Senan S, Paul MA et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized trials. Lancet Oncol 2015; 16 (6): 630–637. doi: 10.1016/S1470-2045 (15) 70168-3.
17. van den Berg LL, Klinkenberg TJ, Groen HJ et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 2015; 10 (5): 826–831. doi: 10.1097/JTO.0000000000000483.
18. ClinicalTrials.gov. Radical resection vs. ablative stereotactic radiotherapy in patients with operable stage I NSCLC (POSTILV). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT01753414.
19. ClinicalTrials.gov. A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy with surgery in patients with peripheral stage I non-small cell lung cancer considered higher risk of complications from surgical resection (SABRTOOTHv1). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT02629458.
20. ClinicalTrials.gov. JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES). [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT02468024.
21. Grills IS, Hope AJ, Guckenberger M et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for earlystage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 2012; 7 (9): 1382–1393. doi: 10.1097/JTO.0b013e318260e00d.
22. Palma D, Lagerwaard F, Rodrigues G et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012; 82 (3): 1149–1156. doi: 10.1016/j.ijrobp.2011.03. 005.
23. Chang JY, Liu H, Balter P et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 2012; 7: 152. doi: 10.1186/1748-717X-7-152.
24. Taremi M, Hope A, Dahele M et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012; 82 (2): 967–973. doi: 10.1016/j.ijrobp.2010.12.039.
25. Onishi H, Yoshiyuki S, Yasuo M et al. Japanese multi-institutional study of stereotactic body radiation therapy for more than 2000 patients with stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 87 (Suppl 2): S9–S10. doi: 10.1016/j.ijrobp.2013.06.031.
26. Shibamoto Y, Baba F, Hashizume C et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: 5-year mature results. Int J Radiat Oncol Biol Phys 2013; 87 (Suppl 2): S34–S35. doi: 10.1016/j.ijrobp.2013.06.092.
27. Modh A, Rimmer A, Shah M et al. Survival and toxicity after stereotactic body radiation therapy for central lung tumors. Int J Radiat Oncol Biol Phys 2013; 87 (Suppl 2): S33. doi: 10.1016/j.ijrobp.2013.06.089.
28. Griffieon GH, Lagerwaard FJ, Haasbeek CJ et al. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol 2013; 107 (3): 403–408. doi: 10.1016/j.radonc.2013.04.026.
29. Brooks ED, Sun B, Zhao L et al. Stereotactic ablative radiation therapy is highly safe and effective for elderly patients with early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017; 98 (4): 900–907. doi: 10.1016/j.ijrobp.2016.12.022.
30. Singh AK, Suescun JA, Stephans KL et al. A Phase 2 randomized study of 2 stereotactic body radiation therapy regimens for medically inoperable patients with node-negative, peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017; 98 (1): 221–222. doi: 10.1016/j.ijrobp.2017.01.040.
31. Chang JY, Balter PA, Dong L et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72 (4): 967–971. doi: 10.1016/j.ijrobp.2008.08.001.
32. Haasbeek CJ, Lagerwaard FJ, Slotman BJ et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011; 6 (12): 2036–2043. doi: 10.1097/JTO.0b013e31822e71d8.
33. Chaudhuri AA, Tang C, Binkley MS et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 2015; 89 (1): 50–56. doi: 10.1016/j.lungcan.2015.04.014.
34. Li Q, Swanick CW, Allen PK et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol 2014; 112 (2): 256–261. doi: 10.1016/j.radonc.2014.07.010.
35. Tekatli H, Haasbeek N, Dahele M et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-small cell lung cancer. J Thorac Oncol 2016; 11 (7): 1081–1089. doi: 10.1016/j.jtho.2016.03.008.
36. Benedict SH, Yenice KM, Followill D et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37 (8): 4078–4101.
37. Xiao Y, Papiez L, Paulus R et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 73 (4): 1235–1242. doi: 10.1016/j.ijrobp.2008.11.019.
38. Tozzi A, Comito T, Alongi F et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol 2013; 8 (1): 148. doi: 10.1186/1748-717X-8-148.
39. Rwigema JC, Parikh SD, Heron DE et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011; 34: 63–69. doi: 10.1097/COC.0b013e3181d270b4.
40. Gurka MK, Collins SP, Slack R et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol 2013; 8: 44. doi: 10.1186/1748-717X-8-44.
41. Zhong J, Patel K, Switchenko J et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 2017; 123 (18): 3486–3493. doi: 10.1002/cncr.30706.
42. Tempero MA, Malafa MP, Al-Hawary M et al. Pancreatic adenocarcinoma. Version 2.2018, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 2018.
43. ClinicalTrials.gov. Pancreatic Cancer Radiotherapy Study Group (Stanford): Phase III trial of FOLFIRINOX +/− SBRT in locally advanced pancreatic cancer patients. [online]. Available from: https: //clinicaltrials.gov/ct2/show/NCT01926197.
44. Benson AlB, D’Angelica MI, Abbott DE et al. Hepatobiliary cancers. Version 3.2018, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 2018.
45. Hoffe SE, Finkelstein SE, Russell MS et al. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control 2010; 17 (2): 100–110. doi: 10.1177/107327481001700205.
46. Wahl DR, Stenmark MH, Tao Y et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34 (5): 452–459. doi: 10.1200/JCO.2015.61.4925.
47. Cardenes HR, Price TR, Perkins SM et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010; 12 (3): 218–225. doi: 10.1007/s12094-010-0492-x.
48. Bujold A, Massey CA, Kim JJ et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13): 1631–1639. doi: 10.1200/JCO.2012.44.1659.
49. Andolino DL, Johnson CS, Maluccio M et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81 (4): e447–e453. doi: 10.1016/j.ijrobp.2011.04.011.
50. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007; 19 (5): 289–301. doi: 10.1016/j.clon.2007.02.007.
51. Krupa P, Ticha H, Kazda T et al. Early toxicity of hypofractionated radiotherapy for prostate cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160 (3): 435–441. doi: 10.5507/bp.2016.008.
52. Buyyounouski MK, Price RA jr, Harris EE et al. Stereotactic body radiotherapy for primary management of early-stage, low-to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010; 76 (5): 1297–1304. doi: 10.1016/j.ijrobp.2009.09.078.
53. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011; 6: 3. doi: 10.1186/1748-717X-6-3.
54. Kang JK, Cho CK, Choi CW et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011; 97 (1): 43–48.
55. Madsen BL, Hsi RA, Pham HT et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67 (4): 1099–1105. doi: 10.1016/j.ijrobp.2006.10.050.
56. Chen LN, Suy S, Uhm S et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013; 8: 58. doi: 10.1186/1748-717X-8-58.
57. Katz AJ, Santoro M, Diblasio F et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013; 8: 118. doi: 10.1186/1748-717X-8-118.
58. King CR, Freeman D, Kaplan I et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013; 109 (2): 217–221. doi: 10.1016/j.radonc.2013.08.030.
59. Yu JB, Cramer LD, Herrin J et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 2014; 32 (12): 1195–1201. doi: 10.1200/JCO.2013.53.8652.
60. Hannan R, Tumati V, Xie XJ et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer – results from a multi-institutional clinical trial. Eur J Cancer 2016; 59: 142–151. doi: 10.1016/j.ejca.2016.02. 014.
61. Padmanabhan R, Pinkawa M, Song DY et al. Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity. Future Oncol 2017; 13 (29): 2697–2708. doi: 10.2217/fon-2017-0073.
62. King CR, Brooks JD, Gill H et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82 (2): 877–882. doi: 10.1016/j.ijrobp.2010.11.054.
63. Mohler JL, Lee RJ, Antonarakis ES et al. Prostate cancer. Version 4.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018.
64. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (1): 8–10. doi: 10.1200/JCO.1995.13.1.8.
65. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8 (6): 378–382. doi: 10.1038/nrclinonc.2011.44.
66. Tree AC, Khoo VS, Eeles RA et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14 (1): e28–e37. doi: 10.1016/S1470-2045 (12) 70510-7.
67. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013; 31 (11): 1384–1390. doi: 10.1200/JCO.2012.45.9651.
68. Palma DA, Olson RA, Harrow S et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 2018; 102 (3): S3–S4. doi: 10.1016/j.ijrobp.2018.06.105.
69. Chang JS, Sethi RA, Barani IJ. Extracranial oligometastases. In: Sethi RA et al (eds). Handbook of evidence-based stereotactic radiosurgery and stereotactic body radiotherapy. Springer International Publishing Switzerland 2016.
70. Chang DT, Swaminath A, Kozak M et al. Stereotactic body radiotherapy for colorectal liver metastases a pooled analysis. Cancer 2011; 117 (17): 4060–4069. doi: 10.1002/cncr.25997.
71. Rule W, Timmerman R, Tong LY et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011; 18 (4): 1081–1087. doi: 10.1245/s10434-010-1405-5.
72. Ricardi U, Filippi AR, Guarneri A et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012; 75 (1): 77–81. doi: 10.1016/j.lungcan.2011.04.021.
73. Baschnagel AM, Mangona VS, Robertson JM et al. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol 2013; 25 (4): 236–241. doi: 10.1016/j.clon.2012.12.005.
74. Sole CV, Lopez Guerra JL, Matute R et al. Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases. Clin Transl Oncol 2013; 15 (6): 484–491. doi: 10.1007/s12094-012-0956-2.
75. Scorsetti M, Arcangeli S, Tozzi A et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013; 86 (2): 336–342. doi: 10.1016/j.ijrobp.2012.12.021.
76. Navarria P, Ascolese AM, Tomatis S et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol 2014; 9 (1): 91. doi: 10.1186/1748-717X-9-91.
77. Singh D, Chen Y, Hare MZ et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to lung. J Thorac Dis 2014; 6 (4): 369–374. doi: 10.3978/j.issn.2072-1439.2013.12.03.
78. Johnson J, Braunstein S, Descovich M et al. SBRT treatment of central chest lesions: experience at the University of California. San Francisco: University of California 2014.
79. Ricco A, Davis J, Rate W et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol 2017; 12 (1): 35. doi: 10.1186/s13014-017-0773-4.
80. Burkon P, Kazda T, Pospisil P et al. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study. Neoplasma 2018; pii: 180731N558. doi: 10.4149/neo_2018_180731N558.
81. Mahadevan A, Blanck O, Lanciano R et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol 2018; 13 (1): 26. doi: 10.1186/s13014-018-0969-2.
82. Wang XS, Rhines LD, Shiu AS et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol 2012; 13 (4): 395–402. doi: 10.1016/S1470-2045 (11) 70384-9.
83. Gerszten PC, Burton SA, Ozhasoglu C et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 2007; 32 (2): 193–199. doi: 10.1097/01.brs.0000251863.76595.a2.
84. Sahgal A, Atenafu EG, Chao S et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 2013; 31 (27): 3426–3431. doi: 10.1200/JCO.2013.50. 1411.
85. Sahgal A, Weinberg V, Ma L et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013; 85 (2): 341–347. doi: 10.1016/j.ijrobp.2012.05.007.
86. Cox BW, Jackson A, Hunt M et al. Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2012; 83 (5): e661–e667. doi: 10.1016/j.ijrobp.2012.01.080.
87. Casamassima F, Livi L, Masciullo S et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys 2012; 82 (2): 919–923. doi: 10.1016/j.ijrobp.2010.11.060.
88. Scorsetti M, Alongi F, Filippi AR et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol 2012; 51 (5): 618–623. doi: 10.3109/0284186X.2011.652738.
89. Franzese C, Franceschini D, Cozzi L et al. Minimally invasive stereotactical radio-ablation of adrenal metastases as an alternative to surgery. Cancer Res Treat 2017; 49 (4): 20–28. doi: 10.4143/crt.2016.057.
90. Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother 2015; 20 (6): 472–483. doi: 10.1016/j.rpor.2014.10.004.
91. Jereczek-Fossa BA, Piperno G, Ronchi S et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 2014; 37 (3): 227–233. doi: 10.1097/COC.0b013e3182610878.
92. Yeung R, Hamm J, Liu M et al. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 2017; 12 (1): 105. doi: 10.1186/s13014-017-0820-1.
93. Bae SH, Kim MS, Cho CK et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012; 106 (2): 138–143. doi: 10.1002/jso.23058.
94. Salama JK, Hasselle MD, Chmura SJ et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012; 118 (11): 2962–2970. doi: 10.1002/cncr.26611.
95. Milano MT, Katz AW, Zhang H et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012; 83 (3): 878–886. doi: 10.1016/j.ijrobp.2011.08.036.
96. Jereczek-Fossa BA, Bossi-Zanetti I, Mauro R et al. CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: a prospective evaluation of 95 patients/118 lesions. Strahlenther Onkol 2013; 189 (6): 448–455. doi: 10.1007/s00066-013-0345-y.
97. Comito T, Cozzi L, Clerici E et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014; 14: 619. doi: 10.1186/1471-2407-14-619.
98. Heron DE, Ferris RL, Karamouzis M et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009; 75 (5): 1493–1500. doi: 10.1016/j.ijrobp.2008.12.075.
99. Cengiz M, Özyiğit G, Yazici G et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 81 (1): 104–109. doi: 10.1016/j.ijrobp.2010.04.027.
100. Hara W, Loo Jr BW, Goffinet DR et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008; 71 (2): 393–400. doi: 10.1016/j.ijrobp.2007.10.027.
101. Kaplan ID, Redrosa I, Martin C et al. Results of a phase I dose escalation study of stereotactic radiosurgery for primary renal tumors. Int J Radiat Oncol Biol Phys 2010; 78 (3): S191. doi: 10.1016/j.ijrobp.2010.07.464.
102. Kemmerer E, Hernandez E, Ferriss JS et al. Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. Int J Radiat Oncol Biol Phys 2013; 85 (1): 129–135. doi: 10.1016/j.ijrobp.2012.02.058.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2019 Issue 1
Most read in this issue
- Malignant Tumors of the Penis – Diagnostics and Therapy
- Stereotactic Body Radiotherapy – Current Indications
- Effect of Tumor Size and p16 Status on Treatment Outcomes – Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors
- Is There a Benefit of HER2-Positive Breast Cancer Subtype Determination in Clinical Practice?